| All rights reserved. |
Almond Street Natural Foods
Your Healthy Resource Center
Health Foods Multivitamins Herbal Formulas Vitamins and Nutritional Supplements
How to make chromium work even better for diabetes
by Robert J. Rowen M.D.
If you're overweight or have diabetes, you probably know that your risk
of having a heart attack is quite high. You probably also know that
chromium can help you lower your risk. But now there's evidence that
you can make chromium work even better. When used with another
nutrient, it can lower your risk even further.
The nutrient is the vitamin biotin. Researchers recently tested it in
combination with chromium. They found that the two nutrients
significantly lower heart attack risk factors.
The researchers selected 30 moderately obese subjects with type-2
diabetes. Then they had the patients take either a placebo or a
biotin/chromium combination.
After just four weeks, the researchers had powerful results. The group
taking the nutrient combination had a significantly reduced risk of heart
attack. The combination significantly improved their triglycerides. It
also improved their LDL/HDL ratio compared to the placebo group.
The participants also excreted more chromium in their urine. That
means that the supplement fixed their chromium deficiency. As this
happened, their glucose tolerance improved. All this means considerable
improvement in lab risk factors!
We've known for some time that chromium is useful in the treatment of
diabetes. But it appears that the use of biotin in combination helps it
work even better. These are two great nutrients that can measurably
improve your diabetes-induced risk factors for heart problems. I suggest
you take 200 mcg daily of chromium picolinate. As for biotin, consider
starting with 1 mg per day. You can find both products at any health
food store.
Yours for better health and medical freedom,
Robert Jay Rowen, MD
Ref: "Chromium picolinate and biotin combination reduces atherogenic
index of plasma in patients with type-2 diabetes mellitus: a
placebo-controlled, double-blinded, randomized clinical trial," Geohas J,
Daly A, et al, American Journal of the Medical Sciences, 2007; 333(3):
145-153.